Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Berruti A, et al. Among authors: fazio n. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184. BMC Cancer. 2014. PMID: 24628963 Free PMC article. Clinical Trial.
Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G. Bodei L, et al. Among authors: fazio n. Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3. Eur J Nucl Med Mol Imaging. 2011. PMID: 21892623 Clinical Trial.
Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.
Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M. Panzuto F, et al. Among authors: fazio n. Neuroendocrinology. 2012;96(1):32-40. doi: 10.1159/000334038. Epub 2011 Dec 28. Neuroendocrinology. 2012. PMID: 22205326
Pregnant with metastatic neuroendocrine tumour of the ovary: what now?
Pistilli B, Grana C, Fazio N, Cavaliere A, Ferrari M, Bodei L, Baio S, Scambia G, Paganelli G, Peccatori F. Pistilli B, et al. Among authors: fazio n. Ecancermedicalscience. 2012;6:240. doi: 10.3332/ecancer.2012.240. Epub 2012 Jan 3. Ecancermedicalscience. 2012. PMID: 22331988 Free PMC article.
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group. Bajetta E, et al. Ann Oncol. 2014 Jul;25(7):1373-1378. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12. Ann Oncol. 2014. PMID: 24728035 Free article. Clinical Trial.
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F. Bajetta E, et al. Among authors: fazio n. Cancer. 2014 Aug 15;120(16):2457-63. doi: 10.1002/cncr.28726. Epub 2014 Apr 18. Cancer. 2014. PMID: 24752410 Free article. Clinical Trial.
396 results